Pharmacokinetic and pharmacodynamic interaction of nadolol with itraconazole, rifampicin and grapefruit juice in healthy volunteers

Journal of Clinical Pharmacology

Volumn 53, Issue 7, 2013, Pages 738-745

  Misaka, Shingen ^a   Miyazaki, Nozomu ^a   Yatabe, Midori S ^a   Ono, Tomoyuki ^a   Shikama, Yayoi ^a   Fukushima, Tetsuhito ^a   Kimura, Junko ^a  

^a FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Grapefruit juice; Itraconazole; Nadolol; OATP1A2; P gp; Pharmacokinetics; Rifampicin

Indexed keywords

AURANTIIN; ITRACONAZOLE; KETOCONAZOLE; METOPROLOL; MULTIDRUG RESISTANCE PROTEIN; NADOLOL; PLACEBO; RIFAMPICIN; WATER;

ABSENCE OF SIDE EFFECTS; ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIASTOLIC BLOOD PRESSURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFECT; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG INHIBITION; DRUG INTERACTION; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG WITHDRAWAL; FOOD DRUG INTERACTION; GRAPE JUICE; GRAPEFRUIT JUICE; HUMAN; HUMAN EXPERIMENT; HYDROPHILICITY; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; OPEN STUDY; PHARMACOLOGICAL PARAMETERS; PLASMA CONCENTRATION-TIME CURVE; PULSE RATE; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SYSTOLIC BLOOD PRESSURE; THORAX PAIN; URINARY EXCRETION;

ADMINISTRATION, ORAL; ADRENERGIC BETA-ANTAGONISTS; ADULT; AREA UNDER CURVE; BEVERAGES; BLOOD PRESSURE; CITRUS PARADISI; CROSS-OVER STUDIES; DRUG INTERACTIONS; FOOD-DRUG INTERACTIONS; HALF-LIFE; HEART RATE; HUMANS; ITRACONAZOLE; MALE; NADOLOL; P-GLYCOPROTEIN; RIFAMPIN; YOUNG ADULT;

EID: 84880299342     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.95     Document Type: Article

References (37)

1. Ho RH, Kim RB. Transporters and drug therapy: implications for drug disposition and disease. Clin Pharmacol Ther. 2005;78:260-277.
2. Bailey DG. Fruit juice inhibition of uptake transport: a new type of food-drug interaction. Br J Clin Pharmacol. 2010;70:645-655.
3. Müller F, Fromm MF. Transporter-mediated drug-drug interactions. Pharmacogenomics. 2011;12:1017-1037.
4. Ma JD, Tsunoda SM, Bertino JS, Jr., Trivedi M, Beale KK, Nafziger AN. Evaluation of in vivo P-glycoprotein phenotyping probes: a need for validation. Clin Pharmacokinet. 2010;49:223-237.
5. Hamman MA, Bruce MA, Haehner-Daniels BD, Hall SD. The effect of rifampin administration on the disposition of fexofenadine. Clin Pharmacol Ther. 2001;69:114-121.
6. Shimizu M, Uno T, Sugawara K, Tateishi T. Effects of itraconazole and diltiazem on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein. Br J Clin Pharmacol. 2006;61:538-544.
7. Glaeser H, Bailey DG, Dresser GK, et al. Intestinal drug transporter expression and the impact of grapefruit juice in humans. Clin Pharmacol Ther. 2007;81:362-370.
8. Bailey DG, Dresser GK, Leake BF, Kim RB. Naringin is a major and selective clinical inhibitor of organic anion-transporting polypeptide 1A2 (OATP1A2) in grapefruit juice. Clin Pharmacol Ther. 2007;81:495-502.
9. 2B1 c.1457C>T polymorphism and apple juice on the pharmacokinetics of fexofenadine and midazolam in humans. Pharmacogenet Genomics. 2011;21:84-93.
10. Westphal K, Weinbrenner A, Zschiesche M, et al. Induction of P-glycoprotein by rifampin increases intestinal secretion of talinolol in human beings: a new type of drug/drug interaction. Clin Pharmacol Ther. 2000;68:345-355.
11. Schwarz UI, Seemann D, Oertel R, et al. Grapefruit juice ingestion significantly reduces talinolol bioavailability. Clin Pharmacol Ther. 2005;77:291-301.
12. Schwarz UI, Hanso H, Oertel R, et al. Induction of intestinal P-glycoprotein by St John's wort reduces the oral bioavailability of talinolol. Clin Pharmacol Ther. 2007;81:669-678.
13. Bernsdorf A, Giessmann T, Modess C, et al. Simvastatin does not influence the intestinal P-glycoprotein and MPR2, and the disposition of talinolol after chronic medication in healthy subjects genotyped for the ABCB1, ABCC2 and SLCO1B1 polymorphisms. Br J Clin Pharmacol. 2006;61:440-450.
14. Shirasaka Y, Kuraoka E, Spahn-Langguth H, Nakanishi T, Langguth P, Tamai I., Species difference in the effect of grapefruit juice on intestinal absorption of talinolol between human and rat. J Pharmacol Exp Ther. 2010;332:181-189.
15. Lilja JJ, Backman JT, Laitila J, Luurila H, Neuvonen PJ. Itraconazole increases but grapefruit juice greatly decreases plasma concentrations of celiprolol. Clin Pharmacol Ther. 2003;73:192-198.
16. Lilja JJ, Niemi M, Neuvonen PJ. Rifampicin reduces plasma concentrations of celiprolol. Eur J Clin Pharmacol. 2004;59:819-824.
17. Lilja JJ, Juntti-Patinen L, Neuvonen PJ. Orange juice substantially reduces the bioavailability of the beta-adrenergic-blocking agent celiprolol. Clin Pharmacol Ther. 2004;75:184-190.
18. Lilja JJ, Backman JT, Neuvonen PJ. Effect of itraconazole on the pharmacokinetics of atenolol. Basic Clin Pharmacol Toxicol. 2005;97:395-398.
19. Lilja JJ, Raaska K, Neuvonen PJ. Effects of orange juice on the pharmacokinetics of atenolol. Eur J Clin Pharmacol. 2005;61:337-340.
20. Lilja JJ, Juntti-Patinen L, Neuvonen PJ. Effect of rifampicin on the pharmacokinetics of atenolol. Basic Clin Pharmacol Toxicol. 2006;98:555-558.
21. Kato Y, Miyazaki T, Kano T, Sugiura T, Kubo Y, Tsuji A. Involvement of influx and efflux transport systems in gastrointestinal absorption of celiprolol. J Pharm Sci. 2009;98:2529-2539.
22. Heel RC, Brogden RN, Pakes GE, Speight TM, Avery GS. Nadolol: a review of its pharmacological properties and therapeutic efficacy in hypertension and angina pectoris. Drugs. 1980;20:1-23.
23. Yang Y, Faustino PJ, Volpe DA, Ellison CD, Lyon RC, Yu LX. Biopharmaceutics classification of selected beta-blockers: solubility and permeability class membership. Mol Pharm. 2007;4:608-614.
24. Terao T, Hisanaga E, Sai Y, Tamai I, Tsuji A. Active secretion of drugs from the small intestinal epithelium in rats by P-glycoprotein functioning as an absorption barrier. J Pharm Pharmacol. 1996; 48:1083-1089.
25. 2B1), and interaction (grapefruit juice) profiles of celiprolol following the oral microdose and therapeutic dose. J Clin Pharmacol. 2012;52:1078-1089.
26. Yamaguchi T, Sekine Y, Hashimoto M. Pharmacokinetics of a new beta-adrenergic blocking agent nadolol in man. Jpn Pharmacol Ther. 1983;11:45-50.
27. Gupta S, Kim J, Gollapudi S. Reversal of daunorubicin resistance in P388/ADR cells by itraconazole. J Clin Invest. 1991;87:1467-1469.
28. Shon JH, Yeo CW, Liu KH, Lee SS, Cha IJ, Shin JG. Itraconazole and rifampin alter significantly the disposition and antihistamine effect of ebastine and its metabolites in healthy participants. J Clin Pharmacol. 2010;50:195-204.
29. Neuvonen PJ, Kantola T, Kivisto KT. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin Pharmacol Ther. 1998;63:332-341.
30. Backman JT, Kivisto KT, Olkkola KT, Neuvonen PJ. The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin. Eur J Clin Pharmacol. 1998;54:53-58.
31. Greiner B, Eichelbaum M, Fritz P, et al. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J Clin Invest. 1999;104:147-153.
32. Fromm MF, Kauffmann HM, Fritz P, et al. The effect of rifampin treatment on intestinal expression of human MRP transporters. Am J Pathol. 2000;157:1575-1580.
33. Kyrklund C, Backman JT, Neuvonen M, Neuvonen PJ. Effect of rifampicin on pravastatin pharmacokinetics in healthy subjects. Br J Clin Pharmacol. 2004;57:181-187.
34. Lam JL, Shugarts SB, Okochi H, Benet LZ. Elucidating the effect of final-day dosing of rifampin in induction studies on hepatic drug disposition and metabolism. J Pharmacol Exp Ther. 2006; 319:864-870.
35. Wu CY, Benet LZ. Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm Res. 2005;22:11-23.
36. Dresser GK, Bailey DG, Leake BF, et al. Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine. Clin Pharmacol Ther. 2002;71:11-20.
37. Sung RJ, Olukotun AY, Baird CL, Huycke EC. Efficacy and safety of oral nadolol for exercise-induced ventricular arrhythmias. Am J Cardiol. 1987;60:15D-20D.